Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Pharmaceutical
IBM Watson Health has seen that being thought of as a pioneering company in applying artificial intelligence (AI) in healthcare can have its pros and cons, from a publicity point of view. 2 July 2019
Pharmaceutical
The Russian government has put forward an initiative for the compulsory licensing of patented drugs produced for exports, so that Russian companies can manufacture and sell drugs protected by a patent, according to recent statements by the press service of the Russian federal government, reports The Pharma Letter’s local correspondent. 1 July 2019
Pharmaceutical
Close on the heels of an alert raised by the US Food and Drug Administration and Health Canada regarding the safety of sodium glucose cotransporter-2 (SGLT-2) inhibitors from Johnson & Johnson (NUSE: JNJ) and Germany-based Boehringer Ingelheim, the Drug Controller General of India (DCGI) has asked drug manufacturers to carry a warning label on all new diabetes drugs, reports The Pharma Letter’s India correspondent. 1 July 2019
Pharmaceutical
Global drugmakers operating in the Russian market are considering optimizing of their local ranges this year, mainly as a result of the introduction of new labeling practices in Russia, starting from January, 1 2020, and with the associated increase of their costs, reports The Pharma Letter’s local correspondent. 1 July 2019
Pharmaceutical
Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications. 28 June 2019
Biotechnology
A new cholera vaccine, in Phase III trials, is expected to be six times cheaper than the three currently available in India, making it more cost-effective for inclusion in public health programs, reports The Pharma Letter’s local correspondent. 27 June 2019
Generics
Ayesha Raghib, associate at IP law firm Powell Gilbert, provides an Expert View on the imminent introduction of legislation that could prompt a spike in pharma litigation. 27 June 2019
Biotechnology
Europe's biggest privately-held biotech BioNTech has been in the news recently, with reports the company could be about to raise just shy of a billion dollars in a US listing. 25 June 2019
Pharmaceutical
The share of domestic drugs in the overall sales structure in the Russian pharmaceutical market reached 58% this year, which is a historical record for Russia in the last 30 years, according to recent statistics published by the Russian Ministry of Health and some local analytical agencies in the field of pharmaceutics, reports The Pharma Letter’s local correspondent. 25 June 2019
Biotechnology
The healthcare industry is at an inflection point with the market now preparing for more cell and gene therapies to be approved, writes Ana Stojanovska, vice president of Commercial Consulting at Xcenda, in an Expert View piece. 21 June 2019
Biotechnology
For Belgium-based drugmaker UCB, EULAR 2019 came at a good time to shed further new light on bimekizumab – which the company itself is billing as its pipeline molecule – in a couple of the indications in which it is showing significant promise. 21 June 2019
article
In the wake of the 21st Century Cures Act (Cures Act), the US Food and Drug Administration was tasked with exploring how real-world evidence (RWE) could be incorporated into regulatory decision-making. 20 June 2019
Pharmaceutical
Now that the warming Spanish sun has gone down on EULAR 2019, it’s worth considering what emerged of note from some of rheumatology’s leading players at the event in Madrid. 20 June 2019
Generics
The evolution of generics in Japan is an interesting story that says much about the differences of this market compared to the US or Europe. This article will try to capture the essence of past events, where we are now, and reasonable assumptions about future directions, writes long-time Japan pharma watcher and president of International Alliances Limited P Reed Maurer in his exclusive column for The Pharma Letter. . 20 June 2019
Generics
Sections of Indian pharmaceutical companies and health groups have expressed concern over a move by the Department of Pharmaceuticals (DoP) for an information dissemination mechanism that could allegedly subvert efforts by Indian manufacturers to release generic drugs, reports The Pharma Letter’s local correspondent. 19 June 2019
Pharmaceutical
US drug major AbbVie and Swiss pharma giant Novartis are the latest to announce production and launch plans in Russia, reports The Pharma Letter’s local correspondent. 17 June 2019
Biotechnology
The flags have been furled, poster boards packed away, and ASCO planners are already getting ready for another year. Now, before attention turns to the next major event, we recap some of the key highlights and learnings from the industry’s preeminent cancer conference. 17 June 2019
Pharmaceutical
This month we delve into the diagnosis and treatment of Friedreich’s Ataxia (FA), a rare inherited genetic disorder affecting approximately one to two people per 50,000.1,2 Pharma’s role in advancing the care of these patients is also explored by Dr Nicola Davies in her exclusive series for The Pharma Letter. 17 June 2019
Pharmaceutical
An Expert View on a burgeoning area that should tempt life science investors and professionals to leave their prejudice behind and take a closer look, from Jeannette VanderMarel, co-founder of The Green Organic Dutchman, the world’s largest organic cannabis producer, and chief executive of 48North Cannabis. 15 June 2019
Pharmaceutical
Marta Diez is the first woman president of Cámara de la Innovación Farmacéutica (CIF), a group representing 23 pharma multinationals with a presence in Chile. 12 June 2019
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze